Navigation Links
PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
Date:2/24/2009

ANNAPOLIS, Md., Feb. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a Phase II study of SparVax(TM) and pharmacokinetic (PK) data for Valortim(R) were presented at the 7th Annual ASM Biodefense and Emerging Diseases Research Meeting, being held in Baltimore, MD, February 22-25, 2009.

David P. Wright, President and Chief Executive Officer of PharmAthene commented, "The ASM conference is among the leading industry meetings of the year for biodefense and we are pleased to be able to showcase advancements in each of our SparVax(TM) and Valortim(R) programs to key policy makers at this important meeting."

"PharmAthene has received tremendous support from a variety of government funding partners, including, the Department of Defense, the Department of Health and Human Services, and the National Institute of Allergy and Infectious Diseases. This unprecedented collaborative effort will help to ensure the development of urgently needed medical countermeasures to meet the biosecurity needs of our Nation and Allies."

SparVax(TM) is a novel second generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for pre and post exposure protection against anthrax infection. Valortim(R), in co-development with Medarex, Inc. (Nasdaq: MEDX), is a fully human monoclonal antibody designed to protect against and treat inhalational anthrax, the most lethal form of illness in humans caused by anthrax.

SparVax(TM) Phase II Clinical Data

Results from a Phase II clinical trial of SparVax(TM) were presented during a poster session by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene. The Phase II trial was designed t
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
2. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
3. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
4. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
5. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
6. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
7. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
8. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
9. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
10. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
11. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... a result of recent discussions with certain shareholders representing ... the Company, after dealing with certain matters including the ... of shareholders on March 26, 2015 (the "Meeting") it ... of directors will take place when the Meeting reconvenes. ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital ... Factual Stock Report coverage on Abattis Bioceuticals ... ATTBF; CSE: ATT): is a specialty biotechnology company ... cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, ... in North America . The ...
(Date:3/25/2015)... SHANGHAI , CAMBRIDGE, Mass. and ... -- WuXi NextCODE, which provides comprehensive capabilities for using the ... deCODE genetics on their publication of the largest studies of ... published today online in Nature Genetics ... date of sequence variation, authored by a team of deCODE ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... 2012  Patients with gynecologic cancer have new hope in ... Center at University Hospitals (UH) Case Medical Center.  A ... is among the first in the nation to launch ... treat ovarian, endometrial and select other cancers. ...
... N.J., Jan. 20, 2012  Insmed Incorporated (Nasdaq CM: ... U.S. Food and Drug Administration (FDA) has lifted ... amikacin for inhalation) in patients with non-tuberculous mycobacteria ... discussions with FDA regarding the clinical hold placed ...
... N.Y., Jan. 19, 2012  Netsmart, the leading provider ... organizations nationwide, today announced the launch of ... highlight the positive clinical and financial impacts provided ... (Logo: http://photos.prnewswire.com/prnh/20110620/NY22778LOGO ) In ...
Cached Biology Technology:UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 2UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 3Insmed Incorporated Provides Corporate Update 2Insmed Incorporated Provides Corporate Update 3EveryDayMatters.com Aims to Raise Awareness and Coordinate Care Between Mental and Physical Health 2EveryDayMatters.com Aims to Raise Awareness and Coordinate Care Between Mental and Physical Health 3
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... that in which they exist naturally, proteins and multiprotein ... they exhibit when in the static form in which ... College of Medicine in a report in the current ... study using electron cryomicroscopy, Dr. Steven Ludtke, assistant professor ...
... place is not a Rudyard Kipling “Just So?story, but an ... results. For a chicken, it’s the difference between having feathers ... of Southern California and mathematicians at Oxford University in the ... To understand patterning on the molecular and the systems level, ...
... novel way of combating diseases related to the immune system, ... and arthritis. The study, funded by the Wellcome Trust, appears ... by the body to fight infection. Scientists previously identified two ... T cells", which attack infected cells, and "regulatory T cells", ...
Cached Biology News:Embryonic patterning makes the feathers fly 2T for two: Scientists show how immune system chooses best way to fight infection 2
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
Luminometers...
cDNA Size Fractionation Columns offer an efficient and convenient method for size-fractioning double-stranded cDNA....
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Biology Products: